Aeterna Zentaris Inc., announced Monday it plans to transfer its discovery library of roughly 100,000 unique compounds to the South Carolina Center for Therapeutic Discovery & Development at the Medical University of South Carolina (MUSC).
The agreement ensures the library's continued for the discovery of the company's drug development candidates in the areas of oncology, neurology, endocrinology and women's health.
The center can make the library available to investigators within the University of South Carolina system without restriction and own any therapeutic compounds discovered outside the company's areas of therapeutic interest.
"This agreement with MUSC is another concrete step in our strategy of streamlining our internal drug discovery programs in order to focus our resources on our late-stage clinical programs, as well as on our commercial activities," Aeterna Zentaris CEO David Dodd said. "This agreement will therefore make it possible to continue drug discovery activities without the costs and risks that they imply. More importantly, it is in line with our overall strategy of transitioning into a commercially operating specialty biopharmaceutical company. We look forward to working with the center and MUSC, with which we have already established a close collaboration for our ZoptEC Phase 3 trial in endometrial cancer."